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Summary Invasion through stromal extracellular matrix (ECM) is part of the complex, multistep process of tumour cell invasion and
metastasis. Our group has previously demonstrated that calcium and calmodulin are important in another step in the metastatic cascade -
that of attachment of cells to ECM. Interestingly, the non-steroidal anti-oestrogen tamoxifen (which also has calmodulin antagonist activity),
used in the treatment of breast cancer and now in metastatic cutaneous melanoma, can inhibit the attachment of normal and neoplastic cells
to ECM. In this study, we investigated whether such drugs, known to inhibit cell attachment, could also subsequently reduce their invasion
through a layer of human fibronectin. We examined the ability of the specific calmodulin antagonist J8, tamoxifen and its two major
metabolites, N-desmethyltamoxifen (N-des) and 4-hydroxytamoxifen (4-OH), as well as the pure anti-oestrogen ICI 182,780 and 17,B-
oestradiol to inhibit invasion of the human cutaneous melanoma cell line, A375-SM, uveal melanoma cells and uveal melanocytes. A375-SM
cells and uveal melanoma cells showed a high level of invasion (15.2% and 33.7% respectively) compared with melanocytes (around 5%)
under the experimental conditions used. Submicromolar concentrations of N-des, tamoxifen, J8 and 17,B-oestradiol significantly reduced the
invasiveness of the A375-SM cell line. The uveal melanoma cells also showed similar inhibition, although at higher concentrations of these
agents. 4-OH and ICI 182, 780 had little or no effect on invasion of A375-SM cells (these were not tested on uveal melanoma cells). All cells
used in this study were found to be negative for type nuclear oestrogen receptors, reinforcing the possibility that tamoxifen and 17,-
oestradiol can act via mechanisms unrelated to binding to classical oestrogen receptors to inhibit tumour cell invasion.
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The prognosis for patients with either cutaneous (Garbe et al,
1995) oruveal melanoma (Bedikian et al, 1981; Rajpal et al, 1983)
is poor once these tumours have metastasized. Metastatic spread
involves several different stages and, in escaping from the primary
tumour and in forming distal metastatic deposits, neoplastic cells
need to attach to and subsequently invade through stromal ECM
(Albini and Colacci, 1993 for review). Metastatic melanoma cells
express a greater range ofadhesion molecules than their non-trans-
formed precursor, the melanocyte (Mortarini and Anichini, 1993).
Initial attachment of cells to ECM proteins then leads to a reorga-
nization of the cell cytoskeleton to form focal adhesions (Van
Leeuwen et al, 1994).
In recent years, our laboratory has investigated the role ofsignal
transduction systems in the early stages of cell attachment and
shown that attachment ofmelanoma cells to ECM proteins appears
to involve intracellular signalling systems, in particular calcium
and calmodulin (MacNeil et al, 1992, 1994). We also demon-
strated that tamoxifen and two ofits major metabolites can inhibit
cell attachment to ECM proteins. Our data suggest that the action
of tamoxifen and metabolites in this respect is as a result of their
ability to inhibit calmodulin activity at micromolar concentrations
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rather than any action on 'classical' oestrogen receptors (MacNeil
et al, 1993).
Recent reviews of chemotherapy and immunomodulatory
therapy for melanoma conclude that metastatic cutaneous
melanoma is particularly resistant to both approaches, and most
single-agent therapies give merely a small extension in the
disease-free interval (Legha, 1988; Feun et al, 1995). Currently,
the most promising approaches involve combined chemotherapy
in which DNA-damaging agents, such as cisplatin, carmustin and
dacarbazine, are administered with tamoxifen. Results to date
suggest that tamoxifen has little to offer as a single-agent therapy
compared with other agents already in use; however, when it is
combined with other agents, a significant extension in the disease-
free interval has been achieved for patients with advanced
metastatic melanoma (Del Prete et al, 1984; McClay et al, 1989,
1992; Buzaid et al, 1991; Cocconi et al, 1992; Fierro et al, 1993;
Reintgen and Saba, 1993). It is not clear, at the time of writing,
how tamoxifen works in combined chemotherapy regimens. There
are few convincing data to indicate the presence of classical high-
affinity nuclear oestrogen receptors (ERs) in cutaneous melanoma,
in contrast to their common occurrence in breast cancer. However,
recent data suggest that tamoxifen can inhibit human melanoma
cell proliferation by interaction with type II oestrogen binding
sites (type II EBS) in human melanoma cells (Piantelli, 1995).
The aim of the present study was to investigate an alternative,
putative tumour-inhibitory mechanism of tamoxifen. We investi-
gated the ability of a specific calmodulin antagonist (J8) and of
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tamoxifen and its major metabolites to affect invasion of cuta-
neous and uveal melanoma cells through human fibronectin. We
report that effective inhibition of cutaneous and uveal melanoma
cell invasion in vitro can be achieved with submicromolar concen-
trations of J8, tamoxifen and N-des. Further, during the course of
these studies, we found that the steroid hormone 17p-oestradiol
could itself achieve a partial but significant inhibition of invasion
at nanomolar concentrations in the cutaneous melanoma cell line.
Invasion of uveal melanoma cells could also be inhibited by 17p-
oestradiol, but much higher micromolar concentrations were
required.
MATERIALS AND METHODS
Fibronectin (from human plasma), trypsin-EDTA, Ham's F12
nutrient mix, Dulbecco's modified essential medium powder with
phenol red indicator (DMEM), insulin, transferrin, collagenase
type IA, ax-tocopherol (vitamin E), hydrocortisone, cholera toxin,
Chelex-100, MCDB-153 medium, tamoxifen, nystatin, 12-
phorbol-13-myristate acetate, 17p-oestradiol (water soluble) and
trypan blue were obtained from Sigma Chemical (Poole, Dorset,
UK). Penicillin/streptomycin, L-glutamine, vitamin concentrate,
non-essential amino acids, Fungizone, sodium pyruvate, Eagle's
modified essential medium with phenol red pH indicator
(EMEM), liquid DMEM (with phenol red pH indicator) and
RPMI-1640 medium (both with and without phenol red) were
purchased from Gibco/BRL (Paisley, UK). Fetal calf serum was
obtained from Globe Pharmaceuticals and neonatal calf serum
from APP (West Midlands, UK). Transwell Inserts were obtained
from Costar UK, High Wycombe, Buckinghamshire, UK. J8 [N-
(6-amino-octyl-5-iodo- 1 -naphthalene)] was a kind gift from
Professor GM Blackburn prepared as described previously in
MacNeil et al (1988). N-des and 4-OH were gifts from Klinge
Pharma, Munich, Germany. ICI 182,780 (x7a-[9-(4,4,5,5,5,-
pentafluoropentasulphinyl)- nonyllestra-1,3,5, (I0)triene-3, 171-
diol1) was a kind gift from Dr AE Wakeling at Zeneca (Alderley
Park, Macclesfield, UK).
Oestrogen and progesterone receptors were examined using
Abbott ER-ICA and PgR-ICA monoclonal kits (Abbott
Laboratories, North Chicago, IL, USA).
Cell lines and culture conditions
The human cutaneous melanoma cell line A375-SM was a
generous gift from IJ Fidler (USA) via MJ Humphries (University
of Manchester, UK). These cells were maintained by serial
passages in EMEM supplemented with penicillin (100 units ml-'),
streptomycin (100 jig ml-'), Fungizone (1.2 ,tg ml-'), L-glutamine
(2 jM), sodium pyruvate (1 mM), vitamin concentrate (1.5% of
100 x stock), non-essential amino acids (1%), sodium bicarbonate
(0.187%) and fetal calf serum (10%) at 37°C in a 5% carbon
dioxide/95% air atmosphere.
Human cutaneous fibroblasts were established from normal
adult human dermis as follows: small pieces ofsplit-thickness skin
grafts from normal human skin were digested in 0.1% trypsin solu-
tion overnight at 4°C, followed by addition of 10% neonatal calf
serum to end the action of the enzyme. The pieces of skin were
washed, then epidermis was separated from the dermis. The
dermis was then further washed and minced before being exposed
to 0.05% collagenase in DMEM supplemented with 10% neonatal
calf serum overnight at 37°C. The digested dermis was then spun
at 200 g for 5 min, then resuspended in 10% DMEM. The fibro-
blasts were maintained by serial passages in DMEM supplemented
with penicillin (100 units ml-'), streptomycin (100 jg ml-'), fungi-
zone (0.6 jig ml-), L-glutamine (2 jM), sodium bicarbonate
(0.375%) and fetal calf serum (10%) at 37°C at 5% carbon
dioxide/95% air atmosphere and used within three passages.
Uveal melanoma cells were cultured from six tumour samples
taken from freshly enucleated eyes containing posterior malignant
melanomas of the uvea as previously described (Goodall et al,
1994). Cells were cultured in DMEM-Ham's F12 (1:1) with 10%
fetal calf serum, insulin (10 jig ml-'), transferrin (10 jig ml'), L-
glutamine (2 mM), penicillin-streptomycin (100 jig ml-'), sodium
bicarbonate (2.44 mg ml-'). Tumour cells were used within five
passages. (All tumours used in this study had been removed by
enucleation as they were considered clinically to be 'high risk'.)
Uveal melanocytes were cultured from the sclera and overlying
outer choroid of freshly enucleated eyes containing posterior,
malignant uveal melanomas as described previously (Goodall et
al, 1994). Cells were cultured in MCDB 153 (calcium concentra-
tion of 0.15 mM) supplemented with 2% chelated fetal calf serum,
insulin (10 jig ml-'), transferrin (10 jig ml-'), hydrocortisone (2.8
jig ml-), L-glutamine (2 mM), penicillin - streptomycin (100 jg
ml-'), nystatin (10 U ml-'), vitamin E (1 jig ml'), cholera toxin
(100 ng ml'), bovine pituitary extract (50 jg ml-'), 12-phorbol-
13-myristate acetate (10 nM). Uveal melanocytes were used within
five passages.
Invasion assay
Transwell inserts, containing a polycarbonate filter with 8-
jim-diameter pores randomly distributed over its surface, were
inverted and 50 jil of human fibronectin (at 10 jig ml') added to
the polycarbonate filter and left for 1 h at 37°C in a 5% carbon
dioxide/95% air atmosphere. The transwells were then placed the
correct way up in wells ofa 24-well plate containing 400 jl ofthe
serum-free medium, in which the cells had been cultured before the
assay. All cell types used in the study were removed from the tissue
culture flasks using 0.5 g 1-' trypsin-0.2 g 1-' EDTA, centrifuged at
250g for 5 min and then resuspended in serum-free medium.
Cell suspensions (150 jl containing approximately 1.2 x 105
cells) plus an equivalent volume of serum-free medium (with or
without drug) were then added to each transwell. Cells were then
left for 20 h at 37°C in a 5% carbon dioxide/95% air atmosphere.
The time of 20 h was chosen as, by this time, sufficient invasion
had occurred, and it was below the doubling time ofthe cells used.
Following examination under the light microscope, all cells in the
experiment were counted using the following techniques. The
medium-cells-drugs mix was collected from the upper and lower
chambers and replaced with an equivalent volume of trypsin-
EDTA to remove the remaining cells from the assay. Cell number
(of trypsinized cells plus any in the media in the upper and lower
chambers) was then determined using a haemocytometer. Invaded
cells were counted as those removed from the underside of the
filter, free floating in the media ofthe 24-well plate or attached to
the bottom of the well. Non-invaded cells were counted as those
remaining in the transwell or attached to the upper surface of the
filter. The percentage ofthe total amount ofcells that had invaded
through fibronectin over 20 h was then calculated.
When the effect of phenol red in the culture media (known to
have oestrogenic properties) on invasion ofthe A375-SM cell line
and uveal melanoma cells was examined, cells were cultured in
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RPMI-1640 media both with and without phenol red for 3 days
before the invasion assay.
Dilution of drugs
J8 was made up as a 10 mm stock solution in 100% dimethyl-
sulphoxide, tamoxifen, N-des and 4-OH were made up as a 10 mm
stock solution in 50% ethanol - 50% acetone, 17,-oestradiol was
made up as a 10 mm stock solution in 1 x phosphate-buffered
saline (PBS) (pH 7.4) and ICI 182,780 was made up to a 10 mm
stock in ethanol and stored in the dark. ICI 182, 780 was further
diluted in ethanol, as required, before a final 1:1000 dilution in
serum-free medium. 17j-Oestradiol was stored at 4°C, then
diluted when needed in serum-free medium. All other drugs were
aliquoted and stored at -20°C and then diluted as required in
serum-free medium.
diaminobenzidine - hydrogen peroxide chromagen. Cells were
counterstained for negativity with 0.5% (aqueous) methyl green. In
all cases, the human breast cancer cell line MCF-7 cultured for 7
days on glass coverslips was used as an assay positive control.
MCF-7 cells cultured in the presence of 10-9M oestradiol for7 days
were used as apositive control for the progesterone receptor assay.
Nuclear immunostaining for ER and PgR was assessed in the
monolayers by two personnel (JWG and LOD) using a dual-
viewing attachment to an Olympus BH-2 light microscope at an
ocular magnification ofx40.
Statistics
Differences between means were tested for statistical significance
using Student's paired or unpaired t-test as appropriate. A value of
P < 0.05 was considered significant.
Cell viability
Cells were cultured in 24-well plates in the presence of the drugs
in serum-free medium for 20 h before harvesting using trypsin-
EDTA. Viability was assessed using trypan blue exclusion. All
drugs were examined in four separate experiments.
Steroid receptor immunocytochemical staining
The A375-SM cell line, human uveal melanoma and melanocytes
were examined for the presence of the ER, and the A375-SM cell
line was co-tested for the presence of the progesterone receptor.
Before staining, the cells to be tested were plated on sterile glass
coverslips in full media (with phenol red); cells were then cultured
under serum-free (with phenol red) conditions for 2 days before
testing for the presence of oestrogen and progesterone receptors.
Routine formaldehyde (3.7%) fixation (with post-fixation in
methanol and acetone) and subsequent immunocytochemical
staining was carried out using Abbott ER or Abbot progesterone
receptor (PgR)-immunocytochemical kits (as described in Merkel
and Osborne, 1988; Walker et al, 1988; Rayter, 1991) with a
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RESULTS
Comparative ability of cells to invade through
fibronectin
Under the conditions of the invasion assay described, uveal
melanoma cells showed a significantly higher level of invasion
(33.7 ± 4%, n = 16) than theA375-SM cell line (15 ± 1.5%, n = 37)
(P <0.0001). Both cell types were significantly more invasive than
the melanocytes (5.1 ± 1.1, n = 11) and the fibroblasts (0.5 ± 0.5, n
= 6, P < 0.001 for all comparisons) (mean ± s.e.m., n = number of
experiments). The uveal melanomas investigated in this study
showed considerable intertumour variation, but much less assay to
assay variation when cells from the same tumour were examined.
Effect of calmodulin antagonist J8 on cell invasion
Figure IA illustrates the combined results ofthree experiments in
which A375-SM cells were cultured with concentrations of J8 up
to 15 gM for the 20 h ofthe invasion assay. These cells proved the
most sensitive to J8 with an IC50 value of0.19 ± 0.06 gM based on
three experiments. Human uveal melanoma cells were much less
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Figure 1 The effects of the specific calmodulin antagonist J8 on the invasion of (A) A375-SM cells and (B) uveal melanoma cells (-) and uveal melanocytes
(a). Results shown are means ± s.e.m. of three experiments for each. Values differing significantly from invasion in the absence of drug are indicated by *P<
0.05 and **P < 0.01 as determined by Student's paired t-test
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Table 1 Sensitivity of cells to calmodulin antagonist, J8, tamoxifen and metabolites, ICI 182,780 and 177p-oestradiol
Agent A375-SM Uveal melanoma Uveal melanocyte
J8 0.19 ±0.16 (n= 3) >15 (n= 3) >15 (n= 3)
Tamoxifen 0.5 ± 0.18 (n = 4) 2.37 ± 0.8 (n = 4) 8 ± 3.5 (n = 5)
N-des 0.083 ± 0.008 (n = 4) 5.33 ± 0.33 (n = 3) > 15 (n = 3)
4-OH >15 (n = 3) -
ICI 182,780 >15 (n = 3)
171-oestradiol 0.1 gM produced 20-25% inhibition 15 gm produced 55.2 ± 6.3% inhibition in
in EMEM with phenol red (n = 7). DMEM-F12 with phenol red (n = 4).
17p-oestradiol 0.1 gM produced 49 ± 7.8% inhibition 15 gM produced a 10.1 ± 2.5% inhibition in
in RPMI-1640 without phenol red (n = 5). RPMI-1640 without phenol red (n = 3).
This table summarizes the concentrations required by these compounds to reduce invasion of the A375-SM cell line, uveal melanoma cells and uveal
melanocytes by 50%. The exception is the data obtained with 17p-oestradiol for which partial inhibition only was achieved, and the degree of inhibition achieved
with 0.1 gM steroid is shown for A375-SM cells and with 15 gM for uveal melanoma cells. Results shown as mean ± s.e.m. based on nexperiments and
expressed in gM.
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Figure 2 The Effects of tamoxifen (0), N-des (@) and 4-OH (0) on invasion of (A) A375-SM cells and (B) uveal melanoma cells. Values shown are means ±
s.e.m. of three experiments with each drug (with the exception of data for tamoxifen on uveal melanoma cells which shows means ± s.e.m. of three replicate
wells of a single representative experiment - IC50 data from four such experiments are given in Table 1). Means differing significantly from invasion in the
absence of drug are indicated by *P < 0.05 and **P < 0.0001 as determined by Student's t-test
sensitive to J8, with an IC50 value in two of the three experiments
of>15 gM (as summarized in Table 1). Human uveal melanocytes
showed a much lower level of invasion under these experimental
circumstances, and there was little cleareffect ofJ8 on this level of
invasion up to the highest concentration examined (15UM), as
depicted in Figure lB. The potency ofJ8 as an antagonist ofinva-
sion ofthe three cell types is summarized in Table 1.
Effect of tamoxifen and metabolites on cell invasion
Tamoxifen, N-des and 4-OH were examined for their effect on
invasion ofA375-SM cells; tamoxifen and N-des were also exam-
ined on uveal melanoma cells and uveal melanocytes IC50 values
are summarized in Table 1.
Tamoxifen and N-des, but not 4-OH, significantly reduced the
invasion ofA375-SM cells as shown in Figure 2A. Submicromolar
concentrations of tamoxifen and N-des achieved approximately
50% inhibition; higher concentrations produced little further inhi-
bition. 4-OH had no significant effect on A375-SM invasion up to
the highest concentration tested (15 gM) as shown in Figure 2A.
With uveal melanoma cells, an essentially similar picture was
seen, with tamoxifen and N-des significantly reducing invasion -
albeit at higher concentrations (4-OH was not tested with these
cells). The uveal melanocytes showed a very low level ofinvasion
which was relatively resistant to the inhibitory effects of both
tamoxifen and N-des (as illustrated in Figure 2B and summarized
in Table 1).
Effects of 17p-oestradiol and the pure anti-oestrogen
receptor antagonist, ICI 182, 780, on A375-SM cell
invasion
To further investigate the mechanism of action of tamoxifen, we
next examined the effects of 17p-oestradiol and the pure anti-
oestrogen ICI 182,780 on A375-SM invasion. Figure 3 shows
combined results of three experiments with each agent examined
over a concentration range from 10 nm to 15 gM, and Table 1 shows
the IC50 values obtained. We initially noticed a slight inhibitory
effect of 17p-oestradiol in our standard culture conditions for the
A375-SM cells. Figure 3A depicts results of three combined
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Figure 3 The effects of (A) 17j-oestradiol in both EMEM media (U) and RPMI-1640 media (OL) and (B) ICI 182,780 on the invasion of A375-SM cells. Results
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Figure 4 The effect of tamoxifen (5 gM), 171-oestradiol (5 gM) and the combined effect of both on the invasion of A375-SM cells. Values shown are means ±
s.e.m. for five combined experiments. **P < 0.05. Invasion in the presence of tamoxifen plus 17p-oestradiol did not differ significantly from that seen with either
agent alone (Student's paired t-test)
Table 2 Effect of media on sensitivity of melanoma cells to 17J-oestradiol
A375-SM cell line Uveal melanoma cells
EMEM with phenol red RPMI-1640 with RPMI-1640 without phenol DMEM-F12 RPMI-1640
phenol red red with phenol red without phenol red
0 100 100 100 100 100
0.001 - 75.7 ± 4.4*** 48+ 8.9*** - -
0.01 78.6 ± 12 45.5 +9.5*** 33 ±2*** 85+ 8.6 120 18.5
0.1 77.3 ± 5.8* 47.7 ± 14.6** 56.6 +2.1* 75 ±6.2* 86.3 11.7
1 77 ± 7.8* 39.7 ± 8.8*** 51 ± 3.5*** 74.6 ± 11 95.5 ± 8.8
5 100 ± 14 39.7 +4.3*** 38 ±9.7*** 77.8± 11.3 79.2 15.4
15 85 ± 1.7** 41.9 +5.1* 48+ 15** 44.8 +6.3*** 77.7+5.5
All values are expressed as a percentage of the level of invasion achieved in absence of the agent. Results are expressed as means± s.e.m. based on three
experiments, with the exception of results of uveal melanoma cells in DMEM-F12 medium, which is based on four experiments. Values differing significantly
from invasion in the absence of 17p-oestradiol are indicated by *P< 0.05, **P< 0.005, ***P < 0.0002.
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Table 3 Comparison of ability of drugs to inhibit cell invasion, compete for oestrogen binding and inhibit calmodulin activity.
Agent IC(50liM) Relative affinity for IC,,(IIM)
invasion oestrogen receptor calmodulin activity
J8 0.2 Not tested 3
Tamoxifen 0.5 la 2
N-des 0.1 0.7 2
4-OH >15 100 2
ICI 182, 780 >15 40-50 Not tested
1703-Oestradiolb 0.1 gMproduced 20-25% inhibition Not tested
17P-Oestradiolc 0.1 gM produced 49% inhibition
This table compares the ability of these drugs to reduce the invasion of the A375-SM cell line, with their known potency for the oestrogen receptor and their
potency to inhibit calmodulin activity. Data for the anti-invasion potency are based on the results of this study; the calmodulin antagonism data are taken from
MacNeil et al (1993), and the oestrogen receptor affinity data is from Croxtall et al (1994). aPotency compared with tamoxifen - tamoxifen potency is referred to
as 1. bcAs shown in Figure 4A, 17,B-oestradiol was only capable of producing a partial inhibition of the order of 20-25% when cell were cultured in EMEMb and
of the order of 49% when cultured in RPMI-1640c.
dose-response experiments (the oneexception is for aconcentration
of5 gM for which the results are based on ten experiments with this
concentration of 173-oestradiol). The overall reduction in invasion
by 5 gIM of 170-oestradiol was of the order of 25%. Also, in one
experiment, cells werepreincubated with 5 gM of17p-oestradiol for
1, 2 or 3 days before addition ofcells to the invasion assay for 20 h.
We found no additive effects of preincubation with 17,-oestradiol
on the inhibitory effects ofthis steroid (results not shown).
We next examined the ability of 17p-oestradiol to reduce the
inhibitory effect of tamoxifen on the invasion of A375-SM cells.
Results of five such experiments in which cells were exposed to
either tamoxifen, 17p-oestradiol or both for the 20 h duration of
the assay are shown in Figure 4. The concentration of tamoxifen
used (5 gM) significantly reduced invasion by approximately 52%
(P = 0.004) in these four experiments; the deliberately high
concentration of 17i-oestradiol (5 gM) used resulted in a 35%
reduction in invasion (P = 0.002). The combined effects ofthe two
agents was to reduce invasion by 28%, which was not significantly
different to that resulting from either agent alone.
Next, we examined the effect of 170-oestradiol on A375-SM
cells cultured in the absence ofphenol red. To do this, we changed
to RPMI-1640 medium (available both with and without phenol
red). Following culture ofcells in RPMI-1640 medium for 3 days
before and during the invasion assay, 17p-oestradiol clearly inhib-
ited A375-SM cell invasion. The presence or absence of phenol
red in the medium, however, did not affect the invasiveness ofthe
cells or their sensitivity to this steroid (as shown in Table 2).
Accordingly, data in the presence and absence ofphenol red were
combined as illustrated in Figure 3A, which shows that cells were
clearly more sensitive to 17f-oestradiol in RPMI-1640 than in
EMEM medium. Thus, in RPMI-1640, 1 nM 17,-oestradiol
decreased invasion by 34 ± 7.9% (P = 0.001), with a maximum
reduction of61.1 ± 3.6% (P < 0.0001) achieved at a concentration
of 5 ,UM (data based on five combined experiments).
Uveal melanoma cells were largely unresponsive to any anti-
invasive effects of17[B-oestradiol until very high concentrations of
steroid were used - as shown in Table 2. This was irrespective of
whether cells were examined in DMEM-F12 medium with phenol
red or RPMI-1640 without phenol red. The pure anti-oestrogenic
compound ICI 182,780 had no significant effect on the invasion of
the A375-SM cells up to 5 ,UM, but, by 15 gM, it had reduced inva-
sion by 36 ± 14% based on three combined experiments as shown
in Figure 3B and summarized in Table 1.
Effects of drugs on viability of A357-SM cells
In order to determine whether the effects of these agents on inva-
sion was due to any cytotoxic effects of the drugs, cell viability
was examined foreach ofthe agents used. With the exception ofJ8
and 4-OH at 15 ,UM, none of the concentrations of drugs signifi-
cantly affected cell viability when incubated with cells under
conditions mimicking the invasion assay (results not shown).
Investigation of the presence of oestrogen and
progesterone receptors
A375-SM, human uveal melanoma cells and uveal melanocytes
were examined forthe presence oftype I oestrogen receptors using
cells that had been cultured serum free (with phenol red) for 2
days. All cells were found negative in contrast to the positive
control MCF-7 breast cancer cells which were shown to be
strongly positive for type I oestrogen receptors and progesterone
receptors.
A375-SM cells were also examined for the presence of proges-
terone receptor in cells cultured in EMEM (with serum and phenol
red) and, again, we were unable to demonstrate the presence of any
progesterone receptors under these conditions (results not shown).
Relationship between ability of drugs to inhibit
invasion, bind to oestrogen receptor and inhibit
calmodulin activity
Table 3 compares the ability ofthe drugs tested to inhibit invasion
of A375-SM cells (tested in this study) with their previously
reported ability to inhibit calmodulin activity and bind to the
oestrogen receptor (reported elsewhere). The table shows that,
whereas J8, tamoxifen and its two major metabolites were equipo-
tent (IC50 of 2-3 gM) in their ability to inhibit calmodulin, their
ability to inhibit invasion and to bind to the oestrogen receptor
varied considerably. The two drugs that had least effect on cell
invasion (4-OH and ICI 182,780) were those with the greatest
affinity for the ER. The three drugs that showed ability to inhibit
cell invasion at submicromolar(IC50 of0.1-0.5 JM) concentrations
(J8, tamoxifen andN-des) were equipotent in theirability to inhibit
calmodulin activity (IC50 of 2-3 JM) but varied in their ability to
bind to classical oestrogen receptors. Finally, partial inhibition
(20-25% in EMEM and 49% in RPMI-1640 media) was also
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achieved with 17p-oestradiol at submicromolar concentrations
(around 0.1 gM).
DISCUSSION
The main aim of this study was to examine whether a specific
calmodulin antagonist (J8) could reduce melanoma cell invasion in
vitro. In relation to this, we also wished to test whether tamoxifen
might reduce melanoma cell invasion, possibly by acting as a
calmodulin antagonist rather than through its ability to compete
with oestrogen binding to oestrogen receptors.
Submicromolar concentrations (non-toxic) of J8, tamoxifen and
N-des effectively reduced the invasion of a human melanoma cell
line, A375-SM, while micromolar concentrations inhibited cells
established from primary uveal melanoma. Additionally, we found
that the actions of tamoxifen could not be fully reversed by the
addition of a high concentration of 17p-oestradiol and that, para-
doxically, 170-oestradiol itself produced a significant inhibition of
A375-SM invasion. To the best of our knowledge, these are novel
observations and may prove to be of clinical relevance.
The invasion ofcells through a layer of ECM, as in this in vitro
assay, is only part of the complex process of metastatic spread
which occurs in vivo (as reviewed in Albini and Colacci, 1993).
Nevertheless, such in vitro invasion assays provide a relatively
simple method for examining differences in invasive phenotype
between neoplastic and normal cells and for investigating the
effects of pharmacological agents on such invasion.
The in vitro invasion assay used for this study proved suffi-
ciently sensitive to allow differences in invasive phenotypes to be
observed between malignant cells, melanocytes and fibroblasts.
Cells cultured from human uveal melanoma tumours also proved
significantly more invasive than their normal non-transformed
counterpart, the uveal melanocyte. However, it was noticeable that
some invasion was observed with uveal melanocytes under the
conditions of this assay. Fibronectin is one of several substrates to
which the uveal melanoma will attach in preference to plastic
(MacNeil et al, 1994). For cells to traverse the layer of fibronectin,
they would need to bind to it, secrete degradative enzymes and
move through it (Albini and Colacci, 1993; Edward and MacKie,
1993). In contrast, cutaneous fibroblasts were relatively poor at
invading through fibronectin (< 1% showing any ability to invade
under the conditions of this assay).
With the relatively low level of invasion seen with the uveal
melanocytes (around 5%), it was sometimes technically difficult to
determine the effect of agents on their invasion; however, we
would have to conclude that there was no convincing effect of J8
or N-des on uveal melanocyte invasion in these experiments.
Relatively high concentrations of tamoxifen did reduce invasion.
The A375-SM cell line was generally more sensitive than the
uveal melanoma cells to the inhibitory effects ofJ8 and tamoxifen.
Uveal melanoma cells showed considerable intertumour varia-
tion which may reflect the metastatic nature of such uveal
melanomas in vivo. In most cases, metastatic spread occurs within
5 years of initial diagnosis, but metastatic spread has, in excep-
tional cases, been recorded up to 42 years after diagnosis (Sheilds
et al, 1985). Once detectable metastases have formed, the patient is
unlikely to survive for more than a few months (Gragoudas, 1991).
In the current study, four out of six tumours were composed
predominantly of epithelioid cells (which have the worst clinical
prognosis; Paul et al, 1962). Unfortunately, given the small
number of tumours used and the predominance of epithelioid
morphology of tumours in the current study, we are unable to
comment on any possible relationship between tumour morph-
ology in vitro and invasive properties in vivo.
Under conditions parallel to those used in the invasion assays,
we were unable to find any evidence of classical high-affinity
oestrogen receptors or indeed progesterone receptors (which
would have been indicative ofactive oestrogen receptors) in any of
the cells used in this study.
The study demonstrates that J8, tamoxifen, N-des and 17f-
oestradiol were all capable of significantly reducing cell invasion
through fibronectin in vitro. To what extent can we make any
deductions about the mechanism of action of these drugs? The
calmodulin antagonist J8 inhibits calmodulin-dependent phospho-
diesterase with an IC50 of around 3 gM, while concentrations
exceeding 1000 gM are required before any significant inhibition
of protein kinase C or transglutaminase activity is seen (MacNeil
et al, 1988). This contrasts to other less specific calmodulin antag-
onists such as the substituted naphthelene sulphonamide W7
which can also, at around 200-300 gM, inhibit protein kinase C
and transglutaminase in vitro (MacNeil et al, 1988). Thus, actions
ofJ8 on invasion through fibronectin are more likely to be attribut-
able to inhibition of calmodulin than to inhibit, for example,
protein kinase C or transglutaminase.
However, calmodulin itself mediates many different actions of
calcium in the cell (e.g. cell proliferation, microtubule disassembly
and secretion of agents from the cell (as reviewed in Tomlinson et
al, 1984). In the current invasion assay, the relatively short dura-
tion (20 h) allows us to exclude any major effect of calmodulin on
cell proliferation. Cells traversing a layer offibronectin might well
be secreting degradative enzymes - calmodulin may influence
this. We have also documented that calmodulin antagonists will
block melanoma cells attaching to ECM proteins; and, here, we
suspect that calmodulin is involved in the transmission of the
ECM-receptor signal into the cell which leads directly or indi-
rectly to the reorganisation of the cytoskeleton. The invasiveness
ofthe A375-SM cells to J8 proved to be more sensitive (IC50 value
of0.2 JM) than we would have predicted from the potency ofJ8 as
an inhibitor of calmodulin (IC50 value of 3 gM based on its ability
to inhibit calmodulin-dependent phosphodiesterase). However, the
former assay is of 20-h duration and the latter of only 15 min,
which may explain the tenfold difference between the performance
of the drug in the two assays. The situation is potentially further
complicated by reports that calmodulin can bind to and activate the
oestrogen receptor with tamoxifen, preventing this activation
(Castoria et al, 1988, 1993; Bouhoute and Leclerq, 1992)
Tamoxifen has a particularly complex pharmacology. If it is
acting as a competitive inhibitor of oestrogen binding to the ER,
then addition of excess oestradiol should reverse its action.
However, this was not the case in this study as only a partial and
insignificant reversal was achieved with oestradiol - indeed, the
steroid itself caused a partial inhibition of invasion. While tamox-
ifen is effective in the treatment of oestrogen receptor positive
breast tumours, some benefit is seen, surprisingly, in approxi-
mately 10% ofreceptor negative patients (Jordan et al, 1988). This
indicates the possible involvement of an alternative inhibitory
mechanism. In this light, a type IIEBS, distinct from the oestrogen
receptor, was discovered (Sutherland et al, 1980) which can bind
tamoxifen (although not the drug ICI 182,780) and may be
induced in both oestrogen receptor negative breast cancer and
melanoma cells inhibited by tamoxifen (Piantelli et al, 1995).
Thus, one explanation for our data is that some of the actions of
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tamoxifen may have been as a result ofits actions on a type II EBS
rather than on a classical nuclear oestrogen binding site. This is
supported, to some extent, by our finding that 4-OH (which has a
higher affinity than tamoxifen for the ER) was relatively ineffec-
tive in blocking invasion ofA375-SM melanoma cells, whereas N-
des (which has a lower affinity than tamoxifen for the ER) was as
potent as tamoxifen in blocking invasion.
The natural ligand for the type II EBS is methyl - p - hydroxy-
phenylactate (Makaveriech et al, 1988), and it is thought that these
receptors can be occupied by flavenoid-like molecules (Piantelli et
al, 1995). The type II EBS has a lower affinity but higher capacity
for oestrogen than the classical oestrogen receptors - they have an
apparent dissociation constant of around 20 nm for oestrogens -
and we found that nanomolar (10-100 nM) concentrations of 17p-
oestradiol inhibited invasion. In this study, the invasive activity of
both A375-SM and uveal melanoma cells was unaffected by the
presence of phenol red (which has oestrogenic properties), also
suggesting that classical oestrogen receptors are not relevant to the
invasive properties ofeither cell type. Uveal melanoma cells were
largely unaffected by physiologically relevant concentrations of
17p-oestradiol in both media examined; in contrast, A375-SM
cells showed an initial inhibitory response to nanomolar concen-
trations of 17p-oestradiol which were clearly medium (but not
phenol) dependent. This illustrates the difficulties of unmasking
such a sex steroid response and may explain why this has not been
reported previously.
Tamoxifen can also influence growth factor production, e.g. by
stimulating the proliferation inhibitory factor TGF-P and
inhibiting the mitogenic factor TGF-oc (Noguchi et al, 1993), and
these effects oftamoxifen should also be considered.
Can we draw any conclusions about whether the actions of
tamoxifen and its two major metabolites inhibit cell invasion via
their ability to inhibit calmodulin activity? Whereas N-des and 4-
OH differ in their affinity for the classical oestrogen receptor, they
are equipotent with tamoxifen in their ability to inhibit calmod-
ulin-dependent phosphodiesterase in vitro and to inhibit melanoma
cell attachment to matrix proteins in vitro (MacNeil et al, 1993). If
all three compounds were inhibiting invasion via any anti-calmod-
ulin activity, then we would expect the three to be roughly equipo-
tent in these assays. However, we found tamoxifen andN-des to be
equipotent in inhibiting invasion whereas 4-OH was relatively
ineffective in inhibiting invasion of A375-SM cells (this metabo-
lite was not tested for its effect on uveal melanoma cells). Also, the
concentrations oftamoxifen andN-des required to reduce invasion
for the A375-SM cells were submicromolar which is unexpectedly
more potent than we would expect of their action if they were
working as calmodulin antagonists (but, as with J8, this may be
explained by the longer duration of the invasion assay). Against
this, however, the concentrations oftamoxifen and N-des required
to inhibit invasion of the uveal melanoma cells were of the same
order as would be expected if they were acting as a calmodulin
antagonist.
It was noticeable that tamoxifen and N-des produced a partial
inhibition of invasion at nanomolar concentrations. No further
inhibition was seen until micromolar concentrations were used.
There are several possible explanations for these observations. If
the two agents are acting via type II EBS, then perhaps nanomolar
concentrations saturate the receptors, causing the initial sharp
decrease in invasion. This would then account for the subsequent
plateau phase. Micromolar concentration of the agents may then
cause further inhibition by another mechanism, e.g. involving
inhibition of calmodulin activity (MacNeil et al, 1988) or indeed
inhibition ofprotein kinase C (O'Brian et al, 1985; Gundimeda et
al, 1996). A further possibility is a heterogeneous population of
cells with one subpopulation highly sensitive to inhibition by
tamoxifen and N-des and a more resistant subpopulation. Further
investigations are needed in this area to clarify this observation.
In summary, our findings with these drugs do not allow us to
draw firm conclusions about their mechanism of action in
melanoma. In the case of J8, it is likely that this drug is acting by
inhibiting calmodulin, but we are not able to say from this study
which intracellular action of calmodulin is relevant to invasion.
With tamoxifen and its metabolites, it is highly unlikely that they
are inhibiting invasion via any action on classical oestrogen recep-
tors, although ourdata would be consistent with an action on atype
II oestrogen receptor binding site. With regard to 17j-oestradiol,
again it is unlikely that this is an action on a classical oestrogen
binding site, but action on a type II EBS cannot be excluded.
This study yields novel data showing three approaches to the
inhibition of melanoma tumour cells in vitro - the use of specific
calmodulin antagonists, the use of tamoxifen and one of its
metabolites and the use of an oestrogen. Findings with tamoxifen
and 173-oestradiol are particularly interesting in view ofthe recent
reported benefit of tamoxifen in combined chemotherapy regi-
mens (Cocconi et al, 1992) and epidemiological data supporting a
female survival benefit in metastatic melanoma (Vossaert et al,
1992; Stidham et al, 1994; Garbe et al, 1995; Karakousis and
Driscoll, 1995).
This area is undoubtedly complex. We suggest that our findings
with tamoxifen and 1713-oestradiol are timely and merit further
investigation because of their potential relevance to the under-
standing and treatment ofmetastatic disease in melanoma.
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